

Alejandra Castanon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2922643/publications.pdf>

Version: 2024-02-01

56
papers

2,208
citations

304743

22
h-index

233421

45
g-index

58
all docs

58
docs citations

58
times ranked

2427
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 disruption to cervical cancer screening in England. <i>Journal of Medical Screening</i> , 2022, 29, 203-208.	2.3	17
2	Acceleration of cervical cancer diagnosis with human papillomavirus testing below age 30: Observational study. <i>International Journal of Cancer</i> , 2022, 150, 1412-1421.	5.1	3
3	Benefit of biennial faecal occult blood screening on colorectal cancer in England: A population-based case-control study. <i>Journal of the National Cancer Institute</i> , 2022, , .	6.3	1
4	HPV vaccination and cervical cancer screening – Authors' reply. <i>Lancet, The</i> , 2022, 399, 1940.	13.7	1
5	As the pandemic evolves so must global monitoring of COVID-19. <i>Public Health</i> , 2022, , .	2.9	0
6	Technological advances: Have they improved standards? Review of outcomes from the Welsh cervical screening programme. <i>Journal of Medical Screening</i> , 2021, 28, 80-87.	2.3	0
7	Recovery strategies following COVID-19 disruption to cervical cancer screening and their impact on excess diagnoses. <i>British Journal of Cancer</i> , 2021, 124, 1361-1365.	6.4	43
8	Cervical screening during the COVID-19 pandemic: optimising recovery strategies. <i>Lancet Public Health, The</i> , 2021, 6, e522-e527.	10.0	37
9	Impact of screening between the ages of 60 and 64 on cumulative rates of cervical cancer to age 84y by screening history at ages 50 to 59: A population-based case-control study. <i>Preventive Medicine</i> , 2021, 149, 106625.	3.4	8
10	Exposure Definition in Case–Control Studies of Cervical Cancer Screening: A Systematic Literature Review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2154-2166.	2.5	3
11	Impact of disruptions and recovery for established cervical screening programs across a range of high-income country program designs, using COVID-19 as an example: A modelled analysis. <i>Preventive Medicine</i> , 2021, 151, 106623.	3.4	34
12	The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. <i>Lancet, The</i> , 2021, 398, 2084-2092.	13.7	305
13	Evidence of HPV vaccination efficacy comes from more than clinical trials. <i>Vaccine</i> , 2020, 38, 5569-5571.	3.8	0
14	Survival from Cervical Cancer Diagnosed Aged 20–29 Years by Age at First Invitation to Screening in England: Population-Based Study. <i>Cancers</i> , 2020, 12, 2079.	3.7	4
15	Impact of changes to cervical screening guidelines on age and interval at which women are tested: Population-based study. <i>Journal of Medical Screening</i> , 2020, 28, 096914132095344.	2.3	2
16	Is a delay in the introduction of human papillomavirus-based cervical screening affordable?. <i>Journal of Medical Screening</i> , 2019, 26, 44-49.	2.3	9
17	Cancer elimination thresholds: one size does not fit all. <i>Lancet Public Health, The</i> , 2019, 4, e86.	10.0	1
18	Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	26

#	ARTICLE	IF	CITATIONS
19	Is the recent increase in cervical cancer in women aged 20â€“24 years in England a cause for concern?. Preventive Medicine, 2018, 107, 21-28.	3.4	26
20	Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study. Lancet Public Health, The, 2018, 3, e34-e43.	10.0	41
21	By how much could screening by primary human papillomavirus testing reduce cervical cancer incidence in England?. Journal of Medical Screening, 2017, 24, 110-112.	2.3	16
22	Cone depth increases risk of adverse obstetric outcomes following treatment for cervical preinvasive disease. Evidence-Based Medicine, 2017, 22, 37-37.	0.6	0
23	Systematic Review and Meta-Analysis of Individual Patient Data to Assess the Sensitivity of Cervical Cytology for Diagnosis of Cervical Cancer in Low- and Middle-Income Countries. Journal of Global Oncology, 2017, 3, 524-538.	0.5	5
24	Cytology in the diagnosis of cervical cancer in symptomatic young women: a retrospective review. British Journal of General Practice, 2016, 66, e871-e879.	1.4	9
25	Is cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix?. International Journal of Cancer, 2016, 139, 1040-1045.	5.1	86
26	Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested caseâ€“control study. British Journal of Cancer, 2016, 115, 1140-1146.	6.4	253
27	Risk of preterm birth following surgical treatment for cervical disease: executive summary of a recent symposium. BJOG: an International Journal of Obstetrics and Gynaecology, 2016, 123, 1426-1429.	2.3	44
28	Evaluating cytology for the detection of invasive cervical cancer. Cytopathology, 2016, 27, 201-209.	0.7	19
29	Is the increased risk of preterm birth following excision for cervical intraepithelial neoplasia restricted to the first birth post treatment?. BJOG: an International Journal of Obstetrics and Gynaecology, 2015, 122, 1191-1199.	2.3	24
30	How many preterm births in England are due to excision of the cervical transformation zone? Nested case control study. BMC Pregnancy and Childbirth, 2015, 15, 232.	2.4	6
31	Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany. Journal of Clinical Microbiology, 2015, 53, 2509-2516.	3.9	73
32	Cervical cancer is not just a young woman's disease. BMJ, The, 2015, 350, h2729-h2729.	6.0	12
33	Cervical cytology and the diagnosis of cervical cancer in older women. Journal of Medical Screening, 2015, 22, 207-212.	2.3	10
34	Benefits and harms of cervical screening from age 20 years compared with screening from age 25 years. British Journal of Cancer, 2014, 110, 1841-1846.	6.4	38
35	Response to comment on â€“Characteristics and screening history of women diagnosed with cervical cancer aged 20â€“29â€“™. British Journal of Cancer, 2014, 111, 2374-2374.	6.4	0
36	Cervical Screening at Age 50â€“64 Years and the Risk of Cervical Cancer at Age 65 Years and Older: Population-Based Case Control Study. PLoS Medicine, 2014, 11, e1001585.	8.4	104

#	ARTICLE	IF	CITATIONS
37	Risk of preterm delivery with increasing depth of excision for cervical intraepithelial neoplasia in England: nested case-control study. <i>BMJ, The</i> , 2014, 349, g6223-g6223.	6.0	86
38	HPV16 L1 and L2 DNA methylation predicts high-grade cervical intraepithelial neoplasia in women with mildly abnormal cervical cytology. <i>International Journal of Cancer</i> , 2013, 133, 637-644.	5.1	56
39	Pregnancy Outcomes After Treatment for Cervical Intraepithelial Neoplasia in a Single NHS Hospital. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 710-715.	2.5	6
40	New Strategies for Human Papillomavirus-Based Cervical Screening. <i>Women's Health</i> , 2013, 9, 443-452.	1.5	26
41	How much could primary human papillomavirus testing reduce cervical cancer incidence and morbidity?. <i>Journal of Medical Screening</i> , 2013, 20, 99-103.	2.3	17
42	Characteristics and screening history of women diagnosed with cervical cancer aged 20-29 years. <i>British Journal of Cancer</i> , 2013, 109, 35-41.	6.4	42
43	Dramatic increase in cervical cancer registrations in young women in 2009 in England unlikely to be due to the new policy not to screen women aged 20-24. <i>Journal of Medical Screening</i> , 2012, 19, 127-132.	2.3	12
44	Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: double-blind, randomised, controlled trial. <i>British Journal of Cancer</i> , 2012, 106, 45-52.	6.4	23
45	Risk of preterm birth after treatment for cervical intraepithelial neoplasia among women attending colposcopy in England: retrospective-prospective cohort study. <i>BMJ, The</i> , 2012, 345, e5174-e5174.	6.0	103
46	Review of cytology and histopathology as part of the NHS Cervical Screening Programme audit of invasive cervical cancers. <i>Cytopathology</i> , 2012, 23, 13-22.	0.7	21
47	Safe thresholds for hybrid capture 2 test in primary cervical screening. <i>BMJ: British Medical Journal</i> , 2011, 342, d2941-d2941.	2.3	2
48	Single negative colposcopy: is it enough to rule out high-grade disease?. <i>Journal of Medical Screening</i> , 2011, 18, 160-161.	2.3	4
49	Response to: Why young women should be screened for cervical cancer: The distinction between CIN2 and CIN3. <i>International Journal of Cancer</i> , 2010, 126, 2257-2258.	5.1	4
50	Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK. <i>British Journal of Cancer</i> , 2010, 102, 933-939.	6.4	79
51	ACOG Guidelines on Cervical Screening: A Step in the Right Direction. <i>Journal of Medical Screening</i> , 2010, 17, 55-56.	2.3	1
52	What is the Right Age for Cervical Cancer Screening?. <i>Women's Health</i> , 2010, 6, 1-4.	1.5	12
53	Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. <i>BMJ: British Medical Journal</i> , 2009, 339, b2968-b2968.	2.3	313
54	How many cervical cancers are prevented by treatment of screen-detected disease in young women?. <i>International Journal of Cancer</i> , 2009, 124, 461-464.	5.1	38

#	ARTICLE	IF	CITATIONS
55	Screening and adenocarcinoma of the cervix. International Journal of Cancer, 2009, 125, 525-529.	5.1	99
56	Prospective observational study: cervical cancer smears. BMJ, The, 0, , b2971.	6.0	0